Company intelligence / Profile preview

SirTLab

Nes-Ziona, Central, Israelsirtlabcorp.com ↗

Ownership: Private
Employees: ~49
Development stage: Commercial

Overview

SirTLab’s pipeline includes at least three named programs using different modalities to boost or restore expression of the sirtuin 6 protein. The lead program is expected to enter human trials in late 2024. All programs are currently in preclinical or IND-enabling stages.

Therapeutic areas: Metabolic DisordersOtherRheumatologyGastroenterologyNeurology
Modalities: Small moleculemRNA-based drugsAdeno-associated virus (AAV) gene therapyAntagonist for micro-RNAs (miRNA therapy)
Industry: Biotech

Drug pipeline

4 assets

SIRT6-mRNA.018

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

No major pharma partnerships disclosed as of June 2025; collaborations with academic leaders noted.

Beyond the preview

Go deeper on SirTLab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SirTLab.

Explore the full profile